Healthcare Industry News: drug-eluting stent
News Release - February 27, 2008
Medtronic Announces First Human Use of Its Bifurcation StentInnovative Heart Device Designed to Treat Bifurcation Lesions Without Overlapping Stents
MINNEAPOLIS--(HSMN NewsFeed)--Seeking to address a challenge facing interventional cardiologists and hundreds of thousands of patients with coronary artery disease worldwide, Medtronic, Inc. (NYSE: MDT ), announced today the first human use of its investigational bifurcation stent. The new stent employs an innovative Y-shaped design to match the anatomy of lesions that form at the junctions of coronary arteries.
Dr. Robert Whitbourn, associate professor and director of the Cardiovascular Research Centre at St. Vincent’s Hospital in Melbourne, performed the first clinical implant of the new device on Feb. 25 as an investigator in the trial, dubbed the BRANCH study. “I left the first case very encouraged by the overall performance of the Medtronic bifurcation stent,” reported Dr. Whitbourn, who also serves as director of the Cardiac Catheterisation Lab and Coronary Intervention at St. Vincent’s. “I was especially impressed with its deliverability and believe it has the potential to treat the majority of true bifurcation lesions across the coronary vasculature. Traditional bifurcation techniques require re-crossing of deployed stent struts, overlapping metal, or the potential risk of incomplete coverage of the bifurcation. This device provides a logical solution for addressing these procedural and technical limitations.”
The BRANCH study is designed to assess the safety and deliverability of the Medtronic bifurcation stent, which differs from other approaches by providing scaffolding to both branches of the bifurcation simultaneously without overlapping stents. The prospective, single-arm trial will enroll up to 60 patients at five sites in Australia and New Zealand. Enrollment is expected to be complete by the end of 2008.
Primary endpoints include cardiac death, myocardial infarction involving the target vessel, and clinically-driven target vessel revascularization (TVR) 30 days post-implant. Other endpoints include device, lesion and procedure success. Expected to be available early in 2009, results from the study will determine whether Medtronic will launch development of a drug-eluting version of the bifurcation stent.
The BRANCH study’s principal investigator is Ian Meredith, professor of cardiology at Monash Medical Centre in Melbourne. “Medtronic’s bifurcation stent provides single-layer, uniform coverage of both the main and side branch,” Meredith explained. “This key feature of the Y-shaped design differentiates it from the current dedicated bifurcation concepts. I am impressed with the flexibility and encouragingly low crossing profile of the stent relative to its design, and believe this new device holds great promise for the treatment of patients with bifurcation lesions, which remain an unsolved clinical challenge in interventional cardiology.”
Of the approximately two million percutaneous coronary interventions (PCIs) performed each year worldwide, an estimated 450,000 (20 percent to 25 percent) involve patients with bifurcation lesions, which are consistently recognized as one of the most difficult lesion types to treat. In addition, PCIs for bifurcation lesions are associated with higher adverse event rates than standard PCIs.
The Medtronic bifurcation stent is intended to reduce the procedural challenges associated with current two-stent bifurcation techniques, which generally require the use of two overlapping stents – one for the main branch, the other for the side branch. Delivered over a dual-wire delivery system through a single catheter, the new stent leverages the latest Medtronic balloon-tapering and -folding technology to minimize the delivery system’s profile. Like other members of Medtronic’s stent portfolio, it is made of an advanced cobalt alloy, which enables the stent struts to be extremely thin while also providing sufficient strength to scaffold the artery. In addition, the investigational bifurcation stent features the same unique modular architecture and custom fusion laser pattern, which have shown excellent deliverability, flexibility and conformability in Medtronic’s commercially available stents (the Driver® bare-metal stent and the Endeavor® drug-eluting stent internationally, including the United States; and the Endeavor Resolute drug-eluting stent outside the United States).
“The innovative design of our bifurcation stent reflects the input of numerous leading physicians on prototype development and preclinical study, as well as feedback from hundreds of other cardiologists around the world,” said Sean Salmon, vice president and general manager of the Coronary and Peripheral Vascular business at Medtronic. “With the start of the BRANCH study, we look forward to continuing our record of innovation through collaboration for the benefit of patients with cardiovascular disease.”
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.